Introduction Executive Summary Chondrosarcoma: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Late Stage Products (Phase III) • Comparative Analysis Drug Name: Company Name • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis INBRX-109: Inhibrx • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early stage products (Phase I) • Comparative Analysis LY3410738: Eli Lilly and Company/ Loxo Oncology • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Chondrosarcoma Key Companies Chondrosarcoma Key Products Chondrosarcoma- Unmet Needs Chondrosarcoma- Market Drivers and Barriers Chondrosarcoma- Future Perspectives and Conclusion Chondrosarcoma Analyst Views Chondrosarcoma Key Companies Appendix

Table 1 Total Products for Chondrosarcoma Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Inhibrx, Inc. • PharmaMar • Agios Pharmaceuticals • Iovance Biotherapeutics • Forma Therapeutics • Eli Lilly and Company • IGM Biosciences, Inc. • AnHeart Therapeutics • Roche • Salarius Pharmaceuticals